Phaseline

Targets › PDE

PDE: drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 2; Other, Genitourinary; next expected readout Oct 2027.

Open in Phaseline: the race on PDE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Western Galilee Hospital-NahariyaPapaverine
Phosphodiesterase inhibitor; non-selective vasodilator
PDEPhase 4Premature Rupture of MembranesOct 2027
Prokrea BCNPKB171
Phosphodiesterase inhibitor (pentoxifylline); increases sperm motility and peripheral bloo
PDEPhase 2Infertility Due to AzoospermiaOct 2027

Conditions

Premature Rupture of Membranes (1) Infertility Due to Azoospermia (1)

Modalities

small molecule (2)

Companies

Western Galilee Hospital-Nahariya (1) Prokrea BCN (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.